
|Videos|January 8, 2018
Could COX-2 Inhibition With Celecoxib Have Role in Breast Cancer?
Author(s)R. Charles Coombes, MD, PhD
This video highlights results of REACT, a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.
Advertisement
In this video, R. Charles Coombes, MD, PhD, of Imperial College London, United Kingdom, discusses results of REACT (Randomised European Celecoxib Trial), a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.
Coombes presented results of this study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Low-Dose CT Screening Reduces Lung Cancer–Specific Mortality
2
FDA Approves Companion Diagnostic for Pembrolizumab in Esophageal/GEJ Carcinoma
3
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
4
Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering
5






















































